vadimezan has been researched along with cediranib in 1 studies
| Studies (vadimezan) | Trials (vadimezan) | Recent Studies (post-2010) (vadimezan) | Studies (cediranib) | Trials (cediranib) | Recent Studies (post-2010) (cediranib) |
|---|---|---|---|---|---|
| 272 | 16 | 101 | 279 | 102 | 204 |
| Protein | Taxonomy | vadimezan (IC50) | cediranib (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.005 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 0.026 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.036 | |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | 0.005 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 0.003 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.0016 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Döme, B; Magyar, M | 1 |
1 review(s) available for vadimezan and cediranib
| Article | Year |
|---|---|
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |